Pages
Posts by category
- Category: Article
- Category: Ask the Experts
- Category: Bioanalytical
- Category: Central Labs
- Category: CMC
- Category: Discovery
- Category: DMPK
- Category: Genomics
- Category: Interview
- Category: Safety and Toxicology
News Items
- John Choi, MS Joins Frontage as the Vice President of Clinical Services
- EPNextS Group and Frontage Laboratories, Inc. Announce Collaboration in Early Phase Clinical Trials
- Frontage Laboratories, Inc. and Telomir Pharmaceuticals, Inc. present Promising Pre-clinical Data for Telomir’s Lead Development Product
- Frontage announces the appointment of Mr. Henry Gao as Chief Financial Officer
- Frontage welcomes Dr. John C. Bernal as VP Global Animal Welfare & Veterinary Resources
- Frontage welcomes Dr. Qi Wei, PhD as Vice President Global Genomic Services
- Frontage Laboratories Acquires Accelera S.r.l.’s Bioanalytical and DMPK Businesses
- Frontage welcomes Dr. Yaodong Huang, PhD as Senior Vice President, ACME
- Frontage announces the appointment of Mr. Henry Gao as President of Asia Pacific
- Frontage announces an initiative to form Global Drug Discovery Services
- Frontage Acquires Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.
- Frontage Receives Multiple 2023 CRO Leadership Awards
- Frontage welcomes Dr. John Kapeghian as the Senior Vice President of Global Safety & Toxicology
- Frontage welcomes Dr. James Huang as VP of Corporate Quality Assurance
- Stewart Jacobson, DVM, DACVP joins Frontage as Vice President, Pathology Services
- Frontage Announces CEO and President Promotions
- Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer’s Drug, Lecanemab
- Stephen Gacheru PhD. joins Frontage as Vice President, Cell and Gene Therapy Operations
- James Houston joins Frontage as Vice President of Information Technology
- Frontage Central Labs is Awarded the Prestigious CAP Accreditation from the College of American Pathologists
- Martin Poirier joins Frontage Laboratories as Executive Director and Head of BRI/Frontage Canada
- Frontage Announces Opening of Custom-Built State-of-the-Art Laboratory Facility in Hayward, CA
- Jeffrey Yablon joins Frontage Laboratories as Senior Vice President
- Frontage Holdings Announces 2022 Interim Results
- Frontage Laboratories Inc. Acquires Frontage Clinical Services Inc.
- Frontage Holdings Announces Annual Results
- Frontage Laboratories Achieves Key Milestone for its Suzhou Toxicology Facility
- Frontage Expands Toxicology Services Through the Acquisition of Experimur
- Frontage Laboratories, Inc is a PanaBIOS Trusted Travel Approved COVID-19 Laboratory Testing Provider.
- Frontage Expands Early Drug Discovery Services through the Acquisition of Heyan Biotech
- Frontage Holdings Announces 2021 Interim Results
- Dr. Raj Yadwad joins Frontage Laboratories as VP Product Development & Manufacturing.
- Frontage Opens a New State-of-the-Art Laboratory Facility in Exton, PA
- Larry Veal joins Frontage Laboratories, Inc. as the Senior Vice President of North America Sales and Marketing
- Frontage Laboratories, Inc. to Acquire Quintara Discovery, Inc.
- Sudendra Rao Ph.D. joins Frontage as Senior Vice President, Human Resources, North America
- Dr. Daniel Schulz-Jander joins Frontage as the Laboratory Head, Frontage Hayward
- John Foster joins Frontage Laboratories, Inc. as Executive Director, Regional Head of Sales, West
- Frontage Announces Full-Service Human Absorption, Metabolism, and Excretion (hAME) Studies with Radiolabeled Compounds at its Clinical Site in Secaucus, NJ.
- Frontage Expands Genomics Services Through the Acquisition of Ocean Ridge Biosciences
- Frontage Holdings Announces 2020 Annual Results
- Frontage Announces Organizational Enhancements to Drive Growth and Integration
- Frontage to Provide Full Service Human Radiolabeled Absorption, Metabolism, and Excretion Study Capabilities in Early 2021
- Mr. Nicholas Pimlett joins Frontage Laboratories, as Vice President of Alliance & Program Management.
- Frontage Holdings Announces 2020 Interim Results
- Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Greater China.
- Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.
- ANVISA Certification
- Frontage expands synthetic & medicinal chemistry and process research & development services by acquisition of ACME Bioscience
- Frontage Laboratories, Inc establishes a QWBA Center of Excellence (COE) in Exton PA
- Frontage develops a 3 in 1 multiplex PK assay for evaluation of hydroxy-chloroquine, chloroquine and azithromycin in human plasma
- Frontage Announces the Appointment of Michael J. Potchoiba, M.S to Head the QWBA-Center of Excellence in Exton, PA.
- Frontage Laboratories, Inc. Response to COVID-19 (May 2020)
- Frontage Appoints Dr. Chengwei Fang as Vice President of China Bioanalytical Services
- Frontage Appoints Dr.Xiuxiu Cheng as Chief Scientific Officer of China CMC
- Frontage Expands Drug Metabolism & Pharmacokinetic (DMPK) Services by Acquiring Biotranex
- Frontage Holdings Announces 2019 Annual Results
- Frontage China will add about 215,000 Square Feet of Lab to Expand DMPK and Preclinical Toxicology Services
- Frontage Laboratories, Inc. Response to COVID-19 (March 2020)
- Frontage Welcomes Glenn Washer, BSc, DABT as Executive Vice President, Global Safety & Toxicology Services
- Frontage Completes Expansion of Bioanalytical Capacity and Capabilities
- Frontage Holdings Corporation Selected into Hang Seng Hong Kong-Listed Biotech Index
- Frontage Expanding Geographic Foothold into Canada and the West Coast of North America by Acquisition of BRI
- Promotions of Dr. John Lin, Dr. Abdul Mutlib, Dr. Dongmei Wang
- Frontage Clinical Services Inc. Successfully Implements the ClinSpark® eSource Platform at its Phase I Clinic
- Frontage Expands DMPK Capabilities by Acquisition of RMI
- Frontage Holdings expands CMC service in China by raising its shareholding in Frontage Suzhou to 75%
- Frontage Expands Bioanalytical Capacity and Capabilities to Support Biologic Drug Development, Biomarkers and Cell and Gene Therapy
- Frontage Holdings launched a new 42,000 sq.ft. lab in Shanghai, China
- Frontage Holdings Announces 2019 Interim Results
- Frontage Clinical Services, Inc. Expands Facilities to Accommodate Tobacco and Nicotine-Related Studies
- Frontage Receives 2019 CRO Leadership Awards
- Frontage Holdings Corporation Celebrates a Successful Initial Public Offering on the HKEx
- Frontage Appoints Sridhar Krishnan as Senior Vice President of Global Operations!
- Frontage Appoints Joe (Yifeng) Gao as Chief Financial Officer (CFO)
- Frontage Sponsors the CABS workshop "Preclinical and Early Phase Development of Biologics and Small Molecules"
- Frontage Receives 2018 CRO Leadership Awards
- Dr. Song Li Awarded Entrepreneur Of The Year®
- Dr. Song Li Wins Healthcare CEO Enterprise Award
- Frontage Appoints Hugh Davis as Chief Business Officer
- Frontage acquires Concord Biosciences
- Frontage announces expansion into Princeton, NJ
- Frontage is pleased to announce the appointment of Dr. Luca C. Matassa to the position of Vice President, Bioanalytical Operations & Client Services
- Frontage announces that Dr. Philip Doren has joined Frontage as the President of Clinical Services
- Frontage's sister company, MacroStat, also a Tigermed Company, wins the 2016 Lilly Global Supplier Award
- Frontage becomes the first CRO to complete GLP validation on Simoa HD-1 Analyzer for Biomarker Analysis
- Frontage's affiliate, Frontida, acquires Sun Pharma's Philly and Aurora facilities
- Frontage Bioanalytical Labs go Paperless
- Meet our newest members of the Clinical team
- Frontage Expands Service Offerings to Agrochemical Companies
- Frontage Doubles Bioanalytical Lab Capacity
- Frontage Appoints Dr. Michael S. Willett as President of Clinical Services
- Frontage Expands Clinical Operations in Secaucus, NJ
- Frontage Laboratories Awarded GROW New Jersey Grant for Clinical Operations Expansion
- Frontage Laboratories Recognized as “Fastest Growing Company” by INC Magazine
- Tigermed and Frontage Laboratories Complete Strategic Investment Agreement
Events
Resources
- CAR-T Cell Therapy Services
- Companion Diagnostics for Alzheimer's Disease
- Metagenomics Services
- Pharmacogenomics Services
- Gene & Cell Therapy Analytical Services
- Biologics Analytical Testing Services
- Biomarkers in Alzheimer's Disease
- CMC-Product Development & Manufacturing Integrated Solutions
- Hepatitis A Virus Infection In Cynomolgus Monkeys Confounds The Safety Evaluation Of A Drug Candidate
- NDA, 505b(2) and ANDA Product Development Services
- Chemistry Services
- Biology Services
- Pharmacology Services
- In Vitro ADME Services
- RNA Sequencing Services
- Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies
- Validating Digital Droplet PCR (ddPCR) Assay with Zero-Inflated Poisson Model
- Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug Delivery System for Cannabinoids
- Analysis of Semi-and Non-Volatile Leachables via an Enhanced HPLC-UV Method
- Cell-Free DNA NGS Testing
- Challenges of Global Drug Development
- Development and validation of an LC-MS/MS method for the quantification of fascin proteins in human serum
- A Competitive Ligand-binding Assay for the Detection of Neutralizing Antibodies Against XTMAB-16
- Validation of a 384 gene hybridization capture-based pharmacogenomics NGS panel: sensitivity, specificity, accuracy, and reproducibility in calling star alleles for drug metabolism genes
- pTau217 Biomarker Assay
- Optimization and standardization of RNA-seq operation to get high-quality sequencing data with heavily degraded RNA samples from tumor
- Biomarkers Assay List - May 2023
- Oncology Services
- Immunoassays for Drug Discovery
- Biologics, Gene and Cell Therapy Services
- Precision Medicine and Companion Diagnostics
- DMPK Virtual Tour
- Genomics Services
- Global Drug Discovery Services Overview
- Testing of Carryover & After MRD Benchtop Stability for Pharmacokinetic Method Validation in Gyrolab Immunoassay Platform
- Clinical Services Overview
- Utilizing Ligand Binding Assays (LBA) and Critical Reagents for Drug Development
- Central Lab Test Menu
- Ligand Binding Assays (LBAs) and Critical Reagents
- Alignment on Laboratory Support for Clinical Trials
- General Practices for Critical Reagents Usage in Bioanalytical Labs
- Frontage Hayward, CA Site Virtual Tour
- High Throughput Sample Analysis Using Gyrolab
- Preclinical Drug Screening Using Gyrolab
- Frontage 760 Site Virtual Tour
- Validation of Ultra-high Sensitive SIMOA Assays for the Quantitation of NF-L and GFAP
- Quantitative Whole-Body Autoradiography (QWBA) and Radiation Dosimetry
- Bioanalysis of antibody-drug conjugates (ADCs) by LC/MS: challenges and solutions
- Sequencing Assays for Biomarker Discovery and Pharmacodynamics in Oncology Studies eBook
- Gut Reaction: Human Microbiome Analysis Insights
- Sterile Nanoemulsion Product Development: Challenges and Future Prospects
- Fact Sheet: Central Lab Services
- GeneTox: A Pivotal Part of Safety Assessment
- GMP Analytical Testing in Gene Therapy Products
- Safety and Toxicology Services Brochure
- Rapid, accurate and highly customizable assay platforms for pharmacogenomic studies
- Guidelines for Developmental and Reproductive Toxicity (DART) Testing
- Human C14 AME (hAME) Services
- 6 Reasons To Do Exploratory Toxicology for Successful GLP Studies
- DART Fact Sheet
- Biomarker and Alzheimer's disease: role of high sensitivity assays and the applications
- Tissue IHC: from R&D to Clinical Lab Testing
- Transcriptome Analysis in Fixed Tumor Biopsy Samples
- Enroll in a Study
- The Next Generation Central Lab
- Biofluid and Exosome Small RNA Sequencing
- 16S rDNA Amplicon Sequencing of Mock Microbial Community Standards
- Liquid Biopsy: Challenges and benefits of cell-free DNA sequencing
- Assay List - May 2023
- Microbiological Testing Considerations for Pharmaceutical Products
- Precision medicine and companion diagnostics
- Companion Diagnostic Biomarkers: Importance, Trend, and Forecast
- DMPK Services Fact Sheet
- The role of genetic toxicology in drug development
- Meeting public health and regulatory demands for next generation consumer products
- Full Service Radiolabeled Human C14 AME (hAME) Studies
- Bioanalytical Methods for Emerging Therapies
- Genomics: A Customized NGS Sequencing
- Neurofilament Light Chain: Method Validation of Quantitation Using the Quanterix Simoa™ Platform and Potential Applications
- Importance of Safety Pharmacology in IND Filings
- Application of ICP-OES/ICP-MS in Pharmaceutical Analysis
- Shanghai, China Virtual Tour - Chinese
- Shanghai, China Virtual Tour - English
- Empowering immune monitoring with ELISpot assays
- Solving Unique ADC Bioanalytical Challenges
- Best Practices in Managing IND Programs with CROs
- Toxicology Services
- Safety Pharmacology Services
- Genetic Toxicology
- Phase 1 Study of OMN54 - Aneustat
- Phase 1 Clinical Development Program
- Safety and Toxicology Virtual Tour
- Gene Therapy Virus Packaging & Quality Control
- Data Management
- Drug Transporters Services
- IND Enabling Services Brochure
- Data Management Infographic
- Instructions For Self Guided Virtual Tour
- Drug-drug Interaction Study of CYP3A4 Inhibitors with Colchicine Oral Solution
- Relative Bioavailability Study of Colchicine Oral Solution and Probenecid/Colchicine Tablets
- Bioanalytical Developments in Cell and Gene Therapies
- No-observed-adverse-effect level (NOAEL) in IND Programs
- Clinical Virtual Tour
- CMC Virtual Tour
- Bioanalytical Virtual Tour
- The Importance of Biomarker Discovery and Personalized Medicine
- BSEPcyte® and MDR3cyte®: Innovative Solutions for Investigating Drug-Induced Liver Injury
- Human Gut Microbiome-Based Contract Research Applications in Toxicology and Microbiome-Based Drug Discovery
- Metabolites in Safety Testing (MIST): Analytical Strategy
- Surrogate Analyte Approaches in Bioanalysis using LC-MS-MS
- MDR3cyte®
- BSEPcyte®
- Strategies and Solutions for Early Phase Formulation Development and CTM Manufacturing
- Development and Validation of an LC-MS.MS Method for the Simultaneous Quantitation of Fifteen Bile Acids in Human Serum
- Cell and Gene Therapy Trends
- First to File Bioequivalency
- IV Infusion
- Complex Diabetes Study
- Requirements for a Derma-Patch Study
- MIST Application Note
- AMAG Pharmaceuticals, Inc. Studies
- Bioanalytical Drug Tolerance Limit Prediction and Optimization Model Developed Through Machine Learning With TensorFlow
- Sterile Product Development of Poorly Water-Soluble Drugs
- Microbiome Services Fact Sheet
- In Vitro BE Study in ANDA Drug Product Development
- Developing an ELISA for residual host cell proteins (HCPs)
- Common Errors in IND-enabling Toxicology Programs
- Stability Testing
- Before GLP: The Value of Robust Exploratory Toxicology
- Analyzing Biomarkers in Drug Development
- IVRT Insights From Frontage CMC Experts
- Accurate Mass: The Best Solution For Metabolite Identification In Discovery...
- Stability Study for EMLA Cream Using In Vitro Percutaneous Absorption
- Evaluating Emerging Tobacco Products and Their Potential Impact on Public Health
- Accurate Determination Of Drug-To-Antibody Ratio Of Interchain...
- Intraperitoneal Dose Administration: Successful Testing Using IP Catheters
- PKI Combo™
- Sustainability Initiatives at Frontage
- An Ultrasensitive LC-APPI-MS/MS Method for Simultaneous Determination...
- Hugh Davis for Contract Pharma
- Antibody Drug Conjugate (ADC)
- Nondetectable Or Minimal Detectable Residue Levels Of N-(N-Butyl)...
- The Use of Modified Rat Vascular Access ButtonsTM to Refine Repeat Blood Sample Collection in Miniature Pigs
- Overcoming Stability Issues in the Development of an LC-MS/MS Method...
- Simultaneous Determination of Coproporphyrin-I and Coproporphyrin-III in Human Plasms and Human Urine Using LC-MS/MS
- Quantitation of Myostatin/GDF-8 in Human Serum Using ELISA
- Achieving sensitive and specific oligonucleotide quantification by hybrid immunoassay and LC–MS/MS
- ADC Bioanalytical Strategies for PK Analysis of Antibody Drug Conjugate...
- Bioanalytical Strategies for PK Analysis of Antibody-Drug Conjugates (ADC) using LC–HRMS & LC–MS/MS
- The Value Of Robust Exploratory Toxicology Testing Prior To Pivotal GLP Studies
- Frontage Holdings Launched A New 42,000 Sq.Ft. Lab In Shanghai, China
- Measuring Biological Activity of Biopharmaceuticals with Cell-Based Assays
- Immunocapture- liquid Chromatography/Mass Spectrometry in...
- Characterization of Positional Isomers of Interchain Cysteine Linked...
- Simultaneous Quantification Of Total Antibody And Antibody-Conjugated...
- Development And Validation Of LC-MS/MS Methods For The...
- Tobacco
- Gene Therapy
- Dr. Song Li, Frontage’s Founder, Ringing The Bell Of The Hong Kong Stock Exchange
- CMC Stability Testing As A Quality Control Measure
- Validating The Simoa Technology
- Gene Therapy Podcast with Hugh Davis
- Outsourcing Analytical Testing For Biologics - A CRO’s Perspective
- Gene Therapy
- Bioanalysis of Liposome Drugs by LC-MS/MS
- Key Points For Success In A Clinical Trial
- Incorporation of microsampling techniques in bioanalytical assays: DBS and capillary microsampling
- Frontage Laboratories Company Overview Brochure
- CMC-Product Development Services
- CMC GMP Analytical Testing for New Chemical Entities and Commercial Product Support
- CMC GMP Analytical Testing for Biologics
- CMC - CTM Manufacturing
- Clinical & Biometrics Services
- Bioanalytical Mass Spectrometry Services
- Bioanalytical Services Overview
- Bioanalytical Large Molecule / Biologics Services
- Bioanalytical Biomarkers
- Agrochemical
- ADC PK Profiling Strategies on LC-MS Platforms: Top-down, Bottom-up...
- Quantitation of Four Chiral Drug Compounds Simultaneously Using...
- Incorporation of Microsampling Techniques in Bioanalytical Assays
- Pre-Existing Antibodies within Immunogenicity Testing
- Specific Quantitation of Antisense Oligonucleotides in Plasma Using MSD
- Method Validation of Quantitation IL-17A in Human Serum using the Ultrasensitive Quanterix Simoa™ Platform
- Characterization of Interchain Cysteine Linked Antibody Drug Conjugates in Mouse Plasma by LC/MS
- Host Cell Protein Testing: Perspective of Current and Future Techniques
- Assessing Pre-Existing Antibodies (PEXA) in Biotherapeutic Development
- A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a Cerebrospinal Fluid Biomarker for Mucopolysaccharidosis II Disease
- Clinical Study of Abuse-Deterrent Formulation to Suppress Release of Hydrocodone
- Developing and Demonstrating Bioequivalence of Semi-Solid Dosage Forms
- Partnership
- Determination of Pregabalinin Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry
- Development and Validation of an Ultra Sensitive LC-MS/MS Method for Quantitation of Midazolam in Human Plasma
- Comparison of the Quantitative Measurement of Albumin in Human...
- Determination of Fluticasone Propionate and Fluticasone 17&[beta]-Carboxylic...
- Validation of a Low-Volume Plasma LC-MS/MS Method Using a Capillary...
- Development of a Neutralizing Antibody Assay to support Clinical Trials
- A Capillary Microsampling (CMS) Technique for Low Volume Bioanalytical...
- Recruiting Women for First-in-Human Trials: Tips for Success
Services & Solutions
Clinical Studies
People
- John Kapeghian, Ph.D.
- James Huang, Ph.D.
- Wentao Zhang, Ph.D.
- Suden Rao, Ph.D.
- Richard Fischetti
- Matt Vaneman
- Henry Gao
- Vishal Gupta, Ph.D.
- Jason Liu, Ph.D.
- Abdul Mutlib, Ph.D.
- John Lin, Ph.D.
- Dongmei Wang, Ph.D.
- Song Li, Ph.D.
News Types
Event Types
Resource Types
